Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase 0.5? FDA Guidance Allows Pre-Clinical Micro-Dose Studies In Human Subjects

This article was originally published in The Pink Sheet Daily

Executive Summary

Aimed at academic researchers, FDA's final guidance permits study of the mechanism of action of new agents at low doses.

You may also be interested in...



Exploratory IND Guidance Emphasizes FDA Flexibility On Data Requirements

The agency believes that industry has not taken full advantage of the flexibility provided in investigational new drug regulations. The draft guidance advises sponsors on how to proceed with early Phase I, short-term "microdosing" studies.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.

Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight

Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel